Article

18 F-FDG uptake heterogeneity predicts KRAS/NRAS/BRAF mutation status in patients with liver metastases of colorectal cancer

2020-05-27

Abstract excerpt

<h4>Background: </h4> Cetuximab and Panitumumab,serve as monoclonal antibodies against the epidermal growth factor receptor (EGFR), have been used in the treatment of metastatic colorectal cancer. However, mutations in KRAS, NRAS, BRAF indicate a lack of response to treatment for EGFR. The identification of KRAS/NRAS/BRAF mutation status is important to improve the success rate of this therapy. PET/CT imaging is a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5ba92acd-e921-5a71-9abe-0ce4714a7225
DOI: 10.21203/rs.3.rs-23443/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

18 F-FDG uptake heterogeneity predicts KRAS/NRAS/BRAF mutation status in patients with liver metastases of colorectal cancerDOI 10.21203/rs.3.rs-23443/v1Read

Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.Semantic proximity Read

Correlation between 18F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer.Semantic proximity Read

Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer.Semantic proximity Read

Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.Semantic proximity Read

Pretreatment 18F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal CancerSemantic proximity Read

Relationship between KRAS mutations and dual time point 18F-FDG PET/CT imaging in colorectal liver metastases.Semantic proximity Read

Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure?Semantic proximity Read

The adiposity of CRLM before targeted therapy initiation may serve as a marker to distinguish KRAS mutation status：A retrospective studySemantic proximity Read

Relationship between PET/CT images and KRAS gene mutations in colorectal cancer in Vietnamese patients.Semantic proximity Read

Genomic and Prognostic Heterogeneity Among RAS/BRAFV600E/TP53 Co-Mutated Resectable Colorectal Liver MetastasesSemantic proximity Read

Clinical impact of KRAS mutation status on recurrence patterns and the efficacy of local therapy after hepatectomy for colorectal liver metastasesSemantic proximity Read

KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liverSemantic proximity Read